Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer

NCT01935934 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01935934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01935934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
May 8, 2013
Completion date
October 24, 2024
Enrollment
102 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial mixed cell adenocarcinoma, endometrial serous adenocarcinoma, metastatic endometrioid adenocarcinoma, recurrent malignant uterine corpus neoplasm, stage iv uterine corpus carcinoma or carcinosarcoma by ajcc v7 stage, stage iva uterine corpus carcinoma or carcinosarcoma by ajcc v7 stage, stage ivb uterine corpus carcinoma or carcinosarcoma by ajcc v7 stage, uterine corpus carcinosarcoma